TransCode Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RNAZ | HURA | SCLP.L | THAT.L | MDNA.TO | TVGN | |
|---|---|---|---|---|---|---|
| Market cap | 27.09M | 109.61M | 116.66M | 9.78M | 40.15M | 95.87M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -2.7 | -2.8 | -370.6 | — | -1.9 | — |
| Price/book | -0.1 | 6.0 | -4.6 | 2.8 | 24.2 | -1.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −82.78% | −33.80% | −12.28% | −4.17% | −72.88% | −75.61% |
| Today | +1.91% | +3.93% | +1.16% | −4.17% | +4.82% | −3.38% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All RNAZ news ›TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.…
Gene Dosage Decoded: New Review Maps Path to Precision Therapy for CMT1A
A new narrative review maps the genetic architecture, regulatory landscape and emerging precision therapies for Charcot-Marie-Tooth disease type 1A. News Source: Juliet Wilcox. (October 28, 2026). Gene Dosage Decoded: New Review Maps Path…
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Molecular residual disease is the tiny amount of cancer that can remain in the body after treatment and is detectable only by sensitive tests that find cancer DNA or other molecular traces. It matters to investors because these…
From the 4Search news index, newest first.
In the news
Mentioned with
Most coverage from
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.